About 20 % of patients whose medical records showed them as being alive with a serious illness were in fact deceased according to California data, leading to hundreds of unnecessary interactions such as appointment reminders, prescription refills and other kinds of wasteful outreach that strain resources and healthcare workers’ time.
FDA drafts new guidance on manufacturing cell and gene therapies, postmarket trial noncompliance
The FDA on Thursday released two new draft guidance documents related to the manufacture of cell and gene therapies, one directing manufacturers to carry out
July 14, 2023